Unknown

Dataset Information

0

Amyloid-? accumulation in the CNS in human growth hormone recipients in the UK.


ABSTRACT: Human-to-human transmission of Creutzfeldt-Jakob disease (CJD) has occurred through medical procedures resulting in iatrogenic CJD (iCJD). One of the commonest causes of iCJD was the use of human pituitary-derived growth hormone (hGH) to treat primary or secondary growth hormone deficiency. As part of a comprehensive tissue-based analysis of the largest cohort yet collected (35 cases) of UK hGH-iCJD cases, we describe the clinicopathological phenotype of hGH-iCJD in the UK. In the 33/35 hGH-iCJD cases with sufficient paraffin-embedded tissue for full pathological examination, we report the accumulation of the amyloid beta (A?) protein associated with Alzheimer's disease (AD) in the brains and cerebral blood vessels in 18/33 hGH-iCJD patients and for the first time in 5/12 hGH recipients who died from causes other than CJD. A? accumulation was markedly less prevalent in age-matched patients who died from sporadic CJD and variant CJD. These results are consistent with the hypothesis that A?, which can accumulate in the pituitary gland, was present in the inoculated hGH preparations and had a seeding effect in the brains of around 50% of all hGH recipients, producing an AD-like neuropathology and cerebral amyloid angiopathy (CAA), regardless of whether CJD neuropathology had occurred. These findings indicate that A? seeding can occur independently and in the absence of the abnormal prion protein in the human brain. Our findings provide further evidence for the prion-like seeding properties of A? and give insights into the possibility of iatrogenic transmission of AD and CAA.

SUBMITTER: Ritchie DL 

PROVIDER: S-EPMC5508038 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


Human-to-human transmission of Creutzfeldt-Jakob disease (CJD) has occurred through medical procedures resulting in iatrogenic CJD (iCJD). One of the commonest causes of iCJD was the use of human pituitary-derived growth hormone (hGH) to treat primary or secondary growth hormone deficiency. As part of a comprehensive tissue-based analysis of the largest cohort yet collected (35 cases) of UK hGH-iCJD cases, we describe the clinicopathological phenotype of hGH-iCJD in the UK. In the 33/35 hGH-iCJD  ...[more]

Similar Datasets

| S-EPMC8403347 | biostudies-literature
| S-EPMC7670151 | biostudies-literature
| S-EPMC10878974 | biostudies-literature
| S-EPMC6708408 | biostudies-literature
| S-EPMC2749815 | biostudies-other
| S-EPMC2373623 | biostudies-literature
| S-EPMC6369772 | biostudies-literature
| S-EPMC4854756 | biostudies-literature
| S-EPMC8706217 | biostudies-literature
| S-EPMC4941209 | biostudies-literature